Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SHUKRAPHAR.NS
HoldFallen FavouriteShukra Pharmaceuticals Limited · Healthcare · India · $252M
38
StockRankGet insider-trade alerts
Q
77
V
15
M
38
P/E (TTM)
71.9x
ROE
24.6%
D/E
0.1x
Dividend %
—
COMPANY DESCRIPTION
Shukra Pharmaceuticals Limited manufactures and markets pharmaceutical products in India and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 588.3M | 745.7M | 325.9M | 567.3M | -1.2% | 748.6M |
| EPS (INR) | 0.02 | 0.42 | 0.22 | 0.50 | 182.1% | 0.78 |
| Shares | 440.8M | 437.9M | 437.9M | 437.9M | -0.7% | 440.8M |
| Debt | 50.8M | 31.5M | 41.8M | 50.2M | -0.4% | 50.2M |
| Equity | 253.0M | 576.3M | 628.4M | 898.5M | 52.6% | — |
| Op CF | 31.7M | -52.0M | 79.2M | 39.3M | 7.4% | 39.3M |
| Inv CF | -44.3M | -12.0M | -12.6M | -141.4M | — | — |
| Fin CF | 49.4M | 124.0M | -45.2M | 40.7M | — | — |
Loading 1Y...
PRICE (1Y)+35.4%
Close
$0.5899
SCORE BREAKDOWN
Quality
77
ROIC
49.6%98.8
ROE
24.6%92.3
GP/Assets
52.2%88.1
Op. Margin
79.1%99.2
FCF/Assets
-10.0%29.4
Piotroski
668.8
Int. Cover
37.3x76.2
D/E Ratio
0.06x69.8
Current Ratio
3.63x62.4
Value
15
P/E (TTM)
71.9x13.6
EV/EBITDA
46.4x12.8
P/FCF
—N/A
P/B
26.8x3.8
P/S
33.0x11.8
Div Yield
—N/A
Momentum
38
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
1159%98.9
FUNDAMENTALS
Market Cap
$252M
P/E (Forward)
—
Gross Margin
81.9%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SHUKRAPHAR.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SHUKRAPHAR.NS | Shukra Pharmaceuticals Limited(you) | $252M | 38 | Hold |
| SIGACHI.NS | Sigachi Industries Limited | $140M | 39 | Hold |
| NOVARTIND.NS | Novartis India Limited | $475M | 30 | Sell |
| INDOCO.NS | Indoco Remedies Limited | $237M | 57 | Hold |
| ORCHPHARMA.NS | Orchid Pharma Limited | $517M | 45 | Hold |
| AMRUTANJAN.NS | Amrutanjan Health Care Limited | $153M | 53 | Hold |
| GUJTHEM.NS | Gujarat Themis Biosyn Limited | $622M | 52 | Hold |
| SUVEN.NS | Suven Life Sciences Limited | $1.1B | 34 | Sell |
| BETA.NS | Beta Drugs Limited | $228M | 72 | Buy |
| SGRL.NS | Shree Ganesh Remedies Limited | $94M | 21 | Sell |
Peer medians: ROE 11.8% · P/E 42.5x · Gross margin 59.4%